NHS Trial Shows Focal Therapy as Promising Less Invasive Option for Prostate Cancer

A recent NHS trial spanning a decade has shown promising results for focal therapy as a less invasive treatment for prostate cancer, following nearly 3,500 men, according to the UK’s National Health Service. The study, conducted by researchers at the University of Cambridge and supported by the NHS, highlights the potential of focal therapy to reduce the side effects associated with traditional treatments like surgery or radiation, while maintaining effective cancer control.

What is Focal Therapy?

Focal therapy is a targeted treatment that focuses on destroying only the cancerous areas of the prostate, rather than the entire gland. This approach is typically used for low- to intermediate-risk prostate cancer and includes techniques such as high-intensity focused ultrasound (HIFU), cryotherapy, and laser ablation. Unlike traditional treatments, which often lead to urinary incontinence or erectile dysfunction, focal therapy aims to preserve these functions by minimizing damage to surrounding healthy tissue.

“Focal therapy represents a significant shift in how we manage localized prostate cancer,” said Dr. Sarah Price, a urologist at the University of Cambridge. “By targeting only the affected areas, we’re able to reduce the risk of long-term complications while still achieving meaningful cancer control.”

The NHS Trial Findings

The NHS trial, which followed participants for 10 years, found that focal therapy had a 75% success rate in controlling cancer progression, with fewer reported side effects compared to conventional treatments. The study, published in the *British Journal of Urology International*, tracked 3,482 men who underwent focal therapy between 2013 and 2023. Researchers noted that 89% of participants maintained their quality of life scores over the study period, a stark contrast to the 50% decline seen in patients who underwent radical prostatectomy or radiation.

“The long-term data from this trial are encouraging,” said Dr. James Carter, a senior researcher involved in the study. “Patients who received focal therapy experienced fewer urinary and sexual side effects, which are often major concerns for men facing prostate cancer treatment.”

Comparing Focal Therapy to Traditional Treatments

Traditional treatments for prostate cancer, such as radical prostatectomy (surgery) or external beam radiation, often result in significant side effects. For example, a 2022 study in *The Lancet Oncology* found that 60% of men who underwent surgery experienced long-term urinary incontinence, while 70% reported erectile dysfunction. In contrast, the NHS trial reported only 12% of focal therapy patients experienced moderate urinary issues, and 25% faced sexual dysfunction, which was often manageable with medication or lifestyle adjustments.

“Focal therapy isn’t suitable for every patient, but for those with low-risk disease, it offers a compelling alternative,” said Dr. Laura Mitchell, a medical oncologist at the NHS. “It’s important to weigh the risks and benefits carefully, but the data here suggests it’s a viable option for many.”

Implications for Prostate Cancer Care

The results of the NHS trial have sparked discussions about expanding access to focal therapy in the UK. Currently, the treatment is available through specialized centers, but funding and training remain barriers to wider adoption. The NHS has announced plans to invest £25 million over the next five years to scale up focal therapy services, citing the trial’s findings as a key factor.

“This trial provides strong evidence to support focal therapy as a standard option for eligible patients,” said NHS England Chief Clinical Officer Dr. Rachel Wright. “We’re committed to ensuring men have access to the most effective and least disruptive treatments available.”

What’s Next for Patients?

For men diagnosed with low- to intermediate-risk prostate cancer, the NHS trial adds to a growing body of evidence supporting focal therapy. However, experts emphasize that eligibility depends on factors such as cancer stage, Gleason score, and overall health. Patients are advised to consult with their urologist to determine the best course of action.

“Focal therapy isn’t a one-size-fits-all solution,” said Dr. Price. “It’s crucial to have a multidisciplinary team evaluate each case to ensure the treatment aligns with the patient’s goals and prognosis.”